Compare Ascendis Pharma A/S (ASND) vs 8x8 Inc (EGHT) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

EGHT trades at $2.05, down 0.49% today, with a bullish technical signal from moving averages. The company shows strong revenue growth with Q4 2026 earnings beating estimates at $0.11 per share versus $0.07 expected. Recent positive news includes AI product launches and industry recognition, though profitability remains weak with a net margin of just 0.22% and negative retained earnings of -$887.72 million.

Outlook is mixed with analyst consensus leaning neutral (39% buy, 43% hold). Key opportunities include AI-driven product expansion and consistent earnings beats, while risks involve high debt levels, thin margins, and competitive pressures in the CPaaS space. The stock's high P/E ratio of 205 suggests growth expectations are priced in.